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enact more stringent price controls. The purpose of this study is to provide empir-
ical evidence on how price regulations in the OECD affected the adoption speed of
new patent-protected pharmaceutical technologies during 1999-2008. METHODS:
We use discrete time duration modelling with parametric and semi-parametric
duration dependence to examine how price expectations shape the probability of
launch, controlling for competition, market size expectations, firm and molecule
heterogeneity across the major OECD markets during 1999-2008. A sub-sample
analysis including only EU countries also investigates the impact of price interde-
pendencies and potential firm strategies in launch and pricing decisions. RESULTS:
The empirical analysis suggests there is a statistically significant and robust price
and market size effect in the adoption of new pharmaceutical technologies. A unit
increase in the log expected launch price and the log of expected market size
increases the probability of launch by 0.003 and 0.002 respectively. Concentrated
therapeutic subgroups, reflecting market crowding constitutes a significant barrier
to entry. Sub-sample findings from the EU market suggest strategic firm behaviour
with firms delaying launch in low-priced markets and attempts to maintain price
differentials across interdependent markets to a minimum due to price comple-
mentarities. Firm economies of scale and the therapeutic importance of innova-
tions are other important drivers of early adoption. CONCLUSIONS: A significant
and robust price and market size effect is observed in the likelihood of new phar-
maceutical adoption. Price regulations slow down pharmaceutical adoption on a
global scale and may impose welfare losses, particularly when the innovations that
are delayed are cost-effective from a societal perspective. Due to scale advantages
observed in international roll-out strategies, price controls may increase incentives
for mergers and acquisitions, further increasing concentration levels and barriers
to entry.
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OBJECTIVES: To understand the role of discounts/rebates impacting medicines
prices in hospitals. METHODS: Qualitative survey with competent authorities and
hospital pharmacists about purchasing strategies for hospital medicines with all
EU Member States and two further European countries (Norway, Turkey) Price
survey (study visits) of 12 active ingredients in 25 hospitals in Austria, the The
Netherlands, Norway, Portugal, Slovakia. RESULTS:Of a total of 27 European coun-
tries, 25 countries reported about the practice of discounts and/or rebates (ex-post
price reductions). The range of the discounts varied among the countries and with
regard to the products. Apart from Italy with mandatory discounts to the NHS,
discounts were always commercial and as such usually kept confidential. Free-cost
medicines (i.e. medicines provided without payment) were reported to be a prac-
tice in six countries, whereas it is legally forbidden in another six countries. In
Austria, the The Netherlands, Portugal, and Slovakia discounts were granted in
individual negotiations between suppliers and hospitals for some of the surveyed
products (e.g., for cardiovascular medicines where generics were available; how-
ever no discounts for all oncology medicines of the sample). In Norway, discounts
played no role since medicines were tendered centrally. In Austria and Slovakia
medicines were provided cost-free to some/all hospitals (only in the indication of
cardiovascular treatment). In Portugal, unit prices of nearly € 0.00 were surveyed
for a few cardiovascular medicines attributable to rebates. CONCLUSIONS: In the
in-patient sector, confidential discounts, and, to a lesser extent, rebates and cost-
free medicines are common in some countries. Discounts are more likely to be
provided where there are (off-patent) therapeutic alternatives available. Large dis-
counts and cost-free provision appear to be a practice for “strategic products”
which account for high volume and expenditure in the out-patient sector.
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OBJECTIVES: The increase in premium-priced orphan drugs coupled with health
care budget constraints will pressure managed care plans to consider restricting
market access. Coverage and reimbursement of ten FDA-designated orphan drugs
(ceramide, alglucerase, modafinil, lamotrigine, laronidase, nitisinone, alpha-gluco-
sidase, galsulfase, idursulfase, bosentan) were analyzed for ten popular Medicare
PDP (AARP, Cigna, CVS Caremark, Humana, Medco, RxAmerica, EmblemHealth,
UniCare, WellCare, FirstHealth.METHODS: Formulary tier structure, out-of-pocket
costs (OPC), monthly retail costs and utilization restrictions (UR)—pre-authoriza-
tion (PA), quantity limits (QL) and step therapy (ST)—were obtained from CMS
(www.medicare.gov). UR were assigned point values reflecting most to least re-
strictive—PA, 3; ST, 2; QL, 1; 6 possible points per drug per plan unless excluded
from formulary. OPC is the percentage of the drugs’ costs paid by patients—an
average of deductible, initial, gap, and catastrophic OPC. Disease incidences were
obtained from a variety of sources. RESULTS: Monthly retail prices ranged from
$19.56 (lamotrigine; generic) to $5,946.37 (bosentan). The drugs excluded from the
most formularies were alglucerase and myozyme (3 each). Lamotrigine, the least
expensive drug, had the highest OPC as a percentage of its retail price (57.58%) on
average among the plans; however, this may be because of its low retail price.
Bosentan had the lowest OPC (36.48%). There was no correlation between drug
price and UR points (r20.030). There were a slight positive correlation between
disease incidence and drug price (r20.219) and between disease incidence and
OPC (r20.380). There were slight negative correlations between a drug’s UR points
and its OPC percentage (r20.163) and between its retail price and OPC (r20.423).
CONCLUSIONS: URs on orphan drugs were prevalent in Medicare plans, with pa-
tients bearing 40-60% of the OPC. The extent of restrictions was not proportional to
the drugs’ price, suggesting that more research is warranted to investigate the
factors related to orphan drug access.
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HOW DOES THE COMMITTEE TO EVALUATE DRUGS (CED) MAKE DECISIONS
ABOUT AMBULATORY PHARMACEUTICAL FUNDING IN ONTARIO?
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OBJECTIVES: Pharmaceutical drug costs represent a large portion of government
health care spending. A national standard to regulate the process of public finan-
cial reimbursement for drugs does not exist in Canada and variations in practices
are evident across the country. The purpose of this study was to provide a compre-
hensive overview of how drug-funding decisions are made in Ontario. METHODS:
Access to Ontario’s Committee to Evaluate Drugs (CED) meeting minutes (July 2009-
July 2010) was granted. A data abstraction form was created based on the frame-
work established by Johnson et al. (2009). For each criterion, importance to the final
decision, strength of evidence and quality of evidence were recorded. Two review-
ers independently extracted the information and consensus was achieved.
RESULTS: Forty-four submissions were included. Five main observations: 1) the
CED considered certain criteria more frequently than others (e.g., clinical benefit
was considered for all decisions, while societal values were discussed less fre-
quently); 2) the relative impact of each criterion on the CED’s recommendation
varied (e.g., overall clinical benefit, efficacy, value for money, and need had the
largest influence); 3) the CED was more likely to discuss the strength of evidence
when its recommendation did not support public funding (e.g., the strength of cost
evidence was discussed 3 times more often for those drugs not recommended for
funding); 4) the frequency with which the CED considered criteria varied according
to whether or not the CED believed there was an established need; and 5) the
majority of the comments made by the CED about the strength of evidence indi-
cated that the quality of the data was low. CONCLUSIONS: This review identified
trends in the influence of different criteria involved in the CED’s drug assessment
process. These results may promote the development and application of a com-
prehensive, consistent, and transparent framework for reimbursement decision-
making.
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BACKGROUND: Pharmaceutical consultation (PC) aims to maximize the successful
outcome of a drug treatment. Although its benefits are well documented, several
different PC models are implemented in various healthcare settings (HCS) and no
optimal model has been identified. OBJECTIVES: To analyze the characteristics of
PC models most relevant to key clinical, monetary, and social objectives, and to
design PC models that optimize them and could be implemented in various HCS
and in primary care in Israel. METHODS:We systematically reviewed studies of PC
programs published from 2000–2010. We analyzed the programs by their organi-
zational characteristics and defined a scale for measuring their success that incor-
porated the clinical, monetary and social objectives. Their results were then scored
accordingly. We calculated the association between each of the key organizational
characteristics and the success score to identify the characteristics that maximize
the program’s success. RESULTS: The analysis revealed three core patterns: con-
sultation to patient and physician, patient alone, and physician alone. For each
pattern, three feasible models for optimal PC were found. The organizational char-
acteristics of each model included the subject and location of the consultation,
target population, consultant’s profession, communication method, incentives,
duration, financing, and the PC process steps. CONCLUSIONS: This method for
optimizing a model for PC program could be implemented in a variety of HCS to
maximize successful drug treatment reflected in the prevention and control of
illnesses, improved clinical outcomes, enhanced well-being of the population and
maximum economic benefits. Interviews with a sample of key players in HCS could
reveal preferences and benefits, which then will be combined with the results of
the previous analysis to optimize a PC program for primary care in Israel and for
other HCS.
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HEALTH OUTCOMES AND ECONOMICS RESEARCH FOR REGENERATIVE
MEDICINE AND CELLULAR THERAPIES: LESSONS FROM A MULTI-MARKET
HEALTH TECHNOLOGY ASSESSMENT AND REIMBURSEMENT REVIEW
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OBJECTIVES: Regenerative medicines, which include cellular and gene therapies,
offer to shift the focus of healthcare from one of palliative care to curative treat-
ment. Because these technologies are novel, more complex than standard biophar-
maceuticals, and often costly, they are anticipated to face heavy scrutiny for mar-
ket access and adoption. The objective of this analysis was to evaluate published
HTAs and reimbursement policies on regenerative medicines for select global mar-
kets, compare them to existing biopharmaceuticals, and evaluate lessons for HEOR
and market access planning. METHODS: A search of HTAs and reimbursement
policies from Australia, Canada, France, Germany, Sweden, the UK (UK) and the
United States (US) was conducted to identify reimbursement recommendations
and key HEOR considerations for this new field. A review of the literature, including
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the Cochrane Library and PubMed was also conducted using relevant MeSH terms
and text words to identify additional reimbursement and HEOR issues associated
with regenerative medicines. RESULTS:Although considered a nascent field, over
40 HTAs and coverage policies on cellular therapies and regenerative medicines
were available from the key Australian, European and North American HTA
agencies and payers considered in the assessment. Many of HTAs and coverage
policies identified gaps in effectiveness data, particularly the lack of compelling
comparative trials and long-term outcomes, and uncertainty surrounding
cost-effectiveness. CONCLUSIONS: While HTAs and payer policies on regenera-
tive medicines reflected decision factors commonly associated with biopharma-
ceuticals, other key market access factors beyond clinical- and cost-effectiveness
were identified that are specific to this field. These factors include involvement of
multiple reimbursable technologies in cell extraction, processing and administra-
tion; cell handling steps that may engage multiple healthcare budgets; and require-
ments to characterize the value of the entire procedure versus the regenerative
medicine alone. Key considerations for HEOR and market access planning are con-
sidered.
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OBJECTIVES: The diffusion of innovative technologies and specifically the differ-
ence between early and mainstream adopters during the product’s life-cycle (also
known as the chasm/saddle phenomena), has been studied empirically. It has been
demonstrated that given a dual-market structure (e.g. early vs. mainstream adopt-
ers) cost has a substantially higher negative impact on mainstream adoption rate
than on early adoption rate. Previous studies focused primarily on the consumer
electronics industry. We examined whether the phenomena of dual-markets ex-
ists also for medical technologies. METHODS: We analyzed the diffusion of inno-
vation patterns of 11 medical interventions using a recent mathematical model:
the Change of Dominance (CD) model, which analyzes the dynamics between the
early and mainstream adopters. Previous research concluded that influences on
adoption and subsequent diffusion rates are very different for various health cat-
egories, technologies, and geographies. Therefore, our empirical dataset covered
three major medical intervention categories: interventional procedures (e.g. coro-
nary stents), pharmaceuticals (e.g. beta-blockers), and diagnostic technologies (e.g.
CT scans). The dataset was collected from five countries: United States, UK, Korea,
Canada and New Zealand.RESULTS:The CD model has an excellent fit (90%) to all
of the technologies analyzed. Nine of the 11 technologies examined (82%) reached
major market adoption. The median time of change of dominance for these nine
technologies was seven years, very similar to that found for consumer electronics.
The adoption rate at the time of CD is 25%, which is higher than the rate in
consumer electronics markets. The CD time of interventional technologies (e.g.
coronary stents, bypass surgery) was substantially lower (3 vs. 8.5 years) compared
to pharmaceuticals or diagnostic technologies. CONCLUSIONS: The dual market
phenomenon seems to occur in the health care, with similar patterns to the con-
sumer electronics industry. Both technology manufacturers and health planners
should consider these findings when attempting to promote the use of innovative
technologies.
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OBJECTIVES: The literature indicates that the expenditure on orphan drugs will be
increasing over the coming years. The market for orphan drugs has inherent mar-
ket characteristics that sometimes result in high prices. The aim of this study was
to analyse whether awarding orphan designation status has an influence on the
price setting of drugs for rare disease indications. METHODS: To this effect, prices
of designated orphan drugs were compared with other non-designated drugs for
rare disease indications. We identified 28 designated orphan drugs and 16 compa-
rable non-designated drugs for rare disease indications for which we collected
official hospital prices (per defined daily dose) in Belgium in 2010. RESULTS: Or-
phan-designated drugs had a higher median price (€138.56 [interquartile range; IQR
€406.57]) than non-designated drugs (€16.55 [IQR €28.05]) for rare disease indica-
tions (p  0.01). CONCLUSIONS: In conclusion, our results suggest that awarding
orphan designation status in itself is associated with higher prices for drugs for rare
disease indications. In order to gain full insight into orphan drug pricing mecha-
nisms, future research should focus on collecting information about the different
factors influencing orphan drug pricing.
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OBJECTIVES: The pharmaceutical-sector is vital for the society and economy as a
whole. Wholesalers are essential for the distribution-chain because they bridge
time and space between supply and demand. Thus, the study aims to draw a
comprehensive picture of the Pharmaceutical-Wholesale-Industry, outlining its
socio-economic importance compared to other forms of distribution with qualita-
tive and quantitative methods, focusing on Germany, U.K., France, Italy, Spain and
the The Netherlands. METHODS: The necessary data was obtained from different
sources: an online-questionnaire was directed to pharmacies, annual GIRP and
IMS-Health statistics; a questionnaire was directed to GIRP-full-member associa-
tions and Wholesale companies (return rate 81%); and systematical literature re-
search which verified the empirical findings. RESULTS: If pooling of medicines
would not be ensured by Wholesalers, each pharmacy would have to contact each
Manufacturer in order to obtain a complete assortment of medicines. The contin-
uous supply of medicines involves more than 4.5bn transactions between Pharma-
cies, Wholesalers and Manufacturers each year. Without Wholesalers this number
would dramatically increase to 99.4bn transactions per year. On average Whole-
salers are bundling products of 21.84 Manufacturers per delivery. The process-
costs of a several order from Wholesalers are €7.98; from Manufacturer €11.36 (cost
differences of 21.84 supplies from direct sales: €240.11). These additional costs have
to be paid by Manufacturers, Pharmacies and finally by Patients. Furthermore,
Wholesalers pre-finance (Ø €11.5bn for 46d) the entire medicine-market and secure
the cash-flow of the social-insurers. Regarding satisfaction with different distribu-
tion-models, the results of the online-questionnaire show that pharmacists are not
satisfied with the new models (satisfaction Wholesalers: 85.17%; Manufacturer:
39.75%; RWA: 9.50%; DTP: 12.2%). CONCLUSIONS:A reduction in number of Whole-
salers will result in a slower supply of medicines, so the existence of the current
distribution system is vital to the European health care sectors, as Pharmaceutical
Wholesalers help reducing transaction-cost, secure a safe, rapid and continuous
supply of medicines.
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OBJECTIVES: To describe the evolution of biosimilars in the EU Member States (MS)
and to identify the key parameters of the EU biosimilars market dynamics across
countries: time to market entry, prices and market penetration. METHODS: A
quantitative analysis of the EU biosimilar market from 2007 to 2010 was conducted
for 26 EU MS. Data was obtained from European Medicines Agency (EMA) and IMS
MIDAS database, including at country level: Date of market entry of reference
products and biosimilars, unit sales and prices (estimated using official prices) of
existing biosimilars and their respective reference products. Descriptive statistics
were applied to summarize the results. Multivariate regression analysis was ap-
plied to identify statistical associations between: 1) time period between the EMA’s
approval and market entry; 2) market penetration (in monetary value); 3) biosimi-
lars DDD prices and the following independent variables: Pharmaceutical market
value, population, Gross National Income, Price Level Index of medicines, total
expenditure on health as % GNI, total expenditure on health in absolute terms,
government expenditure on health and Generic Price Control, International Price
Comparison, Tendering-like practices, Pharmacists generic substitution, INN pre-
scribing, Procedure for pricing and/or reimbursement decision, and Reference Price
System. RESULTS: The market penetration of biosimilars for the three reference
molecules (somatropin, epoietin and filgrastim) rose from 0.33% in 2007 to 15,52%
in 2010. The multivariate analysis show an association between the price level
index, the total and governmental expenditure on health and an earlier market
entry. CONCLUSIONS: Biosimilars hold a certain promise to help bring down the
cost of biologicals to health systems. Existing evidence in the EU is still limited and
the results do not show a clear pattern of market dynamics, although it becomes
evident that biosimilars will attain smaller price reductions and market penetra-
tion than conventional generics.
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OVER-THE-COUNTER STATUS (RX-TO-OTC): A SYSTEMATIC LITERATURE
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OBJECTIVES: To review economic evidence supporting Rx-to-OTC switches.
METHODS: A systematic search of the EMBASE, Pubmed, ISPOR conference ab-
stracts databases and industry associations websites was conducted. The search
was limited to years 2000–2010 and to North America and European countries. Two
independent reviewers selected eligible studies. RESULTS: The search identified 14
reviews, 12 model publications, 12 database analyses, 5 prospective observational
studies and 11 other. Most articles originated from the US. In 5/6 database analyses
and in 8/9 budget impact models (BIM) that quantified cost consequences of Rx-to-
OTC switching, it was shown to generate savings to healthcare budget holders,
mainly due to Rx-drug acquisition savings. Other key direct savings included
avoided: doctor’s visits to obtain a prescription; emergency room visits or hospi-
talisations due to easier access to an effective or safer therapy. Employers’ benefits
included less time-off work to obtain a prescription and less absenteeism and
presenteeism due to easier access to therapies that improve employee productiv-
ity. Cost consequences of potential misuse due to lack of doctor’s supervision were
frequently acknowledged but rarely quantified. The key factors determining the
extent of savings were: uptake rates of the OTC drug among different types of
populations (i.e. those on Rx drugs, other Rx drugs, OTC-treated, untreated and
undiagnosed), therapeutic area and presence of disreimbursement policies. The
only European BIM is old (2004) and showed potential annual savings of €16.4
billion, assuming that 5% of Rx drugs are switched to the OTC status. However, its
use is limited as it is not specific to any drug/disease area and took a simplistic
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